2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1379A
    C14TKL-1 acetate 98%
    C14TKL-1 acetate is the acetate salt form of C14TKL-1 (HY-P1379). C14TKL-1 acetate is a tachykinin-like peptide and exhibits an agonistic activity for neurokinin receptor 1 (NK-1).
    C14TKL-1 acetate
  • HY-P1389A
    Neuropeptide S (human) TFA 98%
    Neuropeptide S human TFA, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human TFA can be used for Alzheimer's disease (AD) research.
    Neuropeptide S (human) TFA
  • HY-P1389S
    Neuropeptide S (human)-13C2,15N
    Neuropeptide S (human)-13C2,15N is the 13C- and 15N-labeled Neuropeptide S (human) (HY-P1389). Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research.
    Neuropeptide S (human)-13C2,15N
  • HY-P1426A
    AmmTX3 TFA 98%
    AmmTX3 TFA is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 TFA is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K+ currents with a Ki of 131 nM. AmmTX3 TFA induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 TFA increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 TFA can be used in research related to pain, epilepsy, and autism spectrum disorder.
    AmmTX3 TFA
  • HY-P1437A
    Neuropeptide S (Mouse) TFA 98%
    Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC50=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca2+. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S (Mouse) TFA
  • HY-P1438A
    Neuropeptide S(Rat) TFA 98%
    Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S(Rat) TFA
  • HY-P1440A
    BeKm-1 TFA 98%
    BeKm-1 TFA is a potent and selective KV11.1 (hERG) channel blocker. BeKm-1 TFA is selective for KV11.1 over a panel of 14 other potassium channels. BeKm-1 TFA dose-dependently prolongs QTc interval in isolated rabbit heart.
    BeKm-1 TFA
  • HY-P1502F
    Biocytin-β-endorphin, human 98%
    Biocytin-β-endorphin, human is abiotinylated β-Endorphin, human (HY-P1502). β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    Biocytin-β-endorphin, human
  • HY-P1726A
    MSG606 TFA 98%
    MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH).
    MSG606 TFA
  • HY-P1840A
    Galanin Receptor Ligand M35 TFA 98%
    Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor (Kd=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a Ki values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.
    Galanin Receptor Ligand M35 TFA
  • HY-P1906A
    [pThr3]-CDK5 Substrate TFA 98%
    [pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM.
    [pThr3]-CDK5 Substrate TFA
  • HY-P1994A
    JMV 170 117829-60-4 98%
    JMV 170, a CCK derivative, is a selective CCK-B agonist. JMV 170 binds to the CCK-B receptor with a 10-fold higher affinity than to the CCK-A receptor. JMV 170 shows contractile effects on pig smooth muscle cells with an EC50 of 9 pmol/L.
    JMV 170
  • HY-P2152A
    Antho-RPamide II hydrochloride 352280-38-7
    Antho-RPamide II hydrochloride is a bioactive neuropeptide. Antho-RPamide II hydrochloride can be isolated for the sea anemone Anthopleura elegantissima. Antho-RPamide II hydrochloride inhibits the spontaneous, rhythmic contractions in tentacle longitudinal muscle fibers of sea anemones.
    Antho-RPamide II hydrochloride
  • HY-P2155A
    BigLEN(rat) TFA 98%
    BigLEN(rat) is a potent GPR171 agonist with an EC50 of 1.6 nM.
    BigLEN(rat) TFA
  • HY-P2210A
    BigLEN(mouse) TFA 98%
    BigLEN(mouse) TFA is a GPR171 agonist. BigLEN(mouse) TFA is a proSAAS-derived neuropeptide. BigLEN(mouse) TFA regulates food intake in mice. BigLEN(mouse) inhibits the release of glutamate onto parvocellular neurons of the paraventricular nucleus in a process dependent upon activation of postsynaptic G proteins.
    BigLEN(mouse) TFA
  • HY-P2243A
    D-JBD19 TFA 98%
    D-JBD19 TFA is a non-permeable peptide. D-JBD19 TFA has neuroprotective effects.
    D-JBD19 TFA
  • HY-P2277A
    PEN (rat) TFA 98%
    PEN (rat) TFA, one of the most abundant hypothalamic neuropeptide and derived from the proprotein ProSAAS, is an endogenous ligand of GPR83.
    PEN (rat) TFA
  • HY-P2298A
    TAT-P4-(DATC5)2 TFA 98%
    TAT-P4-(DATC5)2 TFA is a high-affinity peptide inhibitor of the PICK1 (protein interacting with C kinase-1) PDZ domain, with a Ki of 1.7 nM. TAT-P4-(DATC5)2 TFA can inhibit addiction in rats.
    TAT-P4-(DATC5)2 TFA
  • HY-P2307A
    Tat-NR2Baa TFA 98%
    Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95.
    Tat-NR2Baa TFA
  • HY-P2713A
    OM99-2 TFA 2504147-81-1 98%
    OM99-2 TFA, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a Ki value of 9.58 nM. OM99-2 TFA is significantly advanced the development of BACE1 inhibitor. OM99-2 has the potential for the research of the Alzheimer's disease.
    OM99-2 TFA
Cat. No. Product Name / Synonyms Application Reactivity